Galux, a South Korea-based biotech startup pioneering artificial intelligence (AI)-driven protein therapeutics design, has announced the successful completion of a $29 million (KRW 42 billion) Series B financing. With this round, the company’s total capital raised reaches $47 million (KRW 68 billion).
The Series B round brought together a group of long-term supporters and new institutional backers. InterVest, DAYLI Partners, and PATHWAY Investment participated as existing investors, alongside new investors including Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities, and Mirae Asset Securities.
Galux previously closed an $18 million (KRW 21 billion) Series A financing in 2022, which enabled the company to advance its AI platform and R&D capabilities. Since then, the company has delivered key R&D and business milestones, successfully closing its Series B and reinforcing its execution and growth momentum.
Galux has developed an AI-driven protein design platform, GaluxDesign, which specialises in de novo antibody design, one of the most technically challenging areas in the field. GaluxDesign successfully generated high-affinity antibodies against a range of therapeutic targets and confirmed that its AI-designed antibody structure was highly consistent with the cryo-EM experimental structure, demonstrating both the precision and generalizability of the platform.
The tight integration of pioneering AI with efficient experimental feedback from the company’s internal wet lab is rapidly enhancing the platform’s precision and reliability. Building on this foundation, the platform is being extended to increasingly challenging target classes, including GPCRs and ion channels.
The company has established co-development partnerships with major domestic pharmaceutical companies such as Celltrion and LG Chem, and recently announced a collaboration with Boehringer Ingelheim, marking an important step in its global growth.
Proceeds from this financing round will be used to further enhance its AI platform, expand R&D infrastructure, and accelerate preclinical validation of proprietary pipelines.
